An interventional active/placebo double blinded parallel randomized controlled study in which
at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is
measured along with associated safety and other secondary endpoints like bladder diary
endpoints, quality of life and patient treatment satisfaction.
Patients included in the study must have symptoms of OAB (frequency of at least 8 per day and
Urgency of at least 1 episode per day confirmed by bladder diary).
Patients are not eligible to enroll in the study if they have/had significant hepatic or
renal disease, history of radiation treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.